MedTrace Logo

Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer

NCT00326820 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1404

Last updated 2013-03-13

No results posted yet for this study

Summary

RATIONALE: Ibandronate and zoledronate may help relieve some of the symptoms caused by bone metastases. It is not yet know whether ibandronate is more effective than zoledronate in treating bone metastases from breast cancer.

PURPOSE: This randomized phase III trial is studying ibandronate to see how well it works compared with zoledronate in treating patients with newly diagnosed bone metastases from breast cancer.

Conditions

Interventions

DRUG

ibandronate sodium

DRUG

zoledronic acid

DRUG

Zolendronic Acid

Zoledronic acid 4 mg by intravenous infusion every 4 weeks.

Sponsors & Collaborators

  • Velindre NHS Trust

    collaborator OTHER_GOV

  • Wales Cancer Trials Unit

    lead OTHER

Principal Investigators

  • Peter J. Barrett Lee, MD · Velindre NHS Trust

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2012-12-31
Completion
2015-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00326820 on ClinicalTrials.gov